FDA Approves Casgevy to Treat Beta-Thalassemia

Medically reviewed by Drugs.com.

By Physician’s Briefing Staff HealthDay Reporter

WEDNESDAY, Jan. 17, 2024 -- After approving Casgevy (exagamglogene autotemcel) in December to treat sickle cell disease, the U.S. Food and Drug Administration announced Tuesday that the therapy has now been approved to treat patients older than 12 years with transfusion-dependent beta-thalassemia.

Casgevy is the first CRISPR-based medicine, where gene editing is used to develop the treatment, to be approved for use in the United States. The one-time dose permanently changes DNA in a patient's blood cells, but experts note the relief will not come cheap. The treatment list price is $2.2 million for its use in both sickle cell disease and beta-thalassemia, CNN reported.

"Today's approval is an important step in the advancement of an additional treatment option for individuals with beta-thalassemia," Nicole Verdun, M.D., director of the Office of Therapeutic Products within the FDA Center for Biologics Evaluation and Research, said in an agency news release. "The approval of a cell-based gene therapy for this condition using CRISPR/Cas9 technology reflects FDA's continued commitment to supporting safe and effective treatments that leverage the most promising and cutting-edge medical technologies."

The latest FDA decision was expected, but it comes about two months earlier than the agency's deadline for acting, CNN reported.

To make Casgevy, a person's stem cells are removed and modified using a gene-editing technique called CRISPR/Cas9. The altered cells are then transplanted back into the patient's body, where they multiply and increase the production of hemoglobin, which eases symptoms.

The most common side effects with Casgevy were mouth sores, febrile neutropenia, and decreased appetite, according to the FDA.

CNN Article

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords